Get the Stockscreener App
0.5049
5.06%
-0.0269
After Hours:
.51
0.0051
+1.01%
Sangamo Therapeutics Inc stock is traded at $0.5049, with a volume of 4.98M.
It is down -5.06% in the last 24 hours and down -2.43% over the past month.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
See More
Previous Close:
$0.5318
Open:
$0.53
24h Volume:
4.98M
Relative Volume:
0.90
Market Cap:
$152.33M
Revenue:
$52.29M
Net Income/Loss:
$-134.84M
P/E Ratio:
-0.6732
EPS:
-0.75
Net Cash Flow:
$-117.11M
1W Performance:
-7.73%
1M Performance:
-2.43%
6M Performance:
-49.32%
1Y Performance:
-37.71%
1-Day Range:
$0.5015
$0.532
1-Week Range:
$0.5015
$0.56
52-Week Range:
$0.4111
$3.179
Sangamo Therapeutics Inc Stock (SGMO) Company Profile
Name
Sangamo Therapeutics Inc
Sector
Industry
Phone
(510) 970-6000
Address
501 CANAL BLVD., RICHMOND, CA
Compare SGMO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SGMO
Sangamo Therapeutics Inc
|
0.5049 | 160.45M | 52.29M | -134.84M | -117.11M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-13-24 | Upgrade | Truist | Hold → Buy |
| Dec-10-24 | Reiterated | H.C. Wainwright | Buy |
| Nov-03-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Apr-28-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Feb-27-23 | Upgrade | Wedbush | Neutral → Outperform |
| Jan-06-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-13-22 | Resumed | Wedbush | Neutral |
| May-04-21 | Initiated | RBC Capital Mkts | Outperform |
| Jan-07-21 | Resumed | Guggenheim | Neutral |
| Jan-06-21 | Initiated | Stifel | Hold |
| Dec-16-20 | Resumed | H.C. Wainwright | Buy |
| Sep-08-20 | Initiated | BofA Securities | Buy |
| Jul-07-20 | Initiated | SunTrust | Buy |
| Aug-26-19 | Initiated | H.C. Wainwright | Buy |
| Nov-14-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-09-18 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-10-18 | Initiated | Guggenheim | Buy |
| Jun-20-18 | Initiated | BofA/Merrill | Buy |
| Nov-15-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-22-17 | Resumed | Jefferies | Buy |
| Nov-01-16 | Downgrade | Wedbush | Outperform → Neutral |
| Oct-19-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Dec-04-15 | Initiated | Wells Fargo | Outperform |
| Oct-23-15 | Resumed | Jefferies | Buy |
| May-03-13 | Initiated | BioLogic Equity Research | Sell |
| Feb-23-11 | Reiterated | JMP Securities | Mkt Outperform |
| Jul-29-10 | Reiterated | Wedbush | Outperform |
| Oct-19-09 | Initiated | Brean Murray | Sell |
| Oct-07-09 | Reiterated | Leerink Swann | Outperform |
| Aug-25-09 | Reiterated | JMP Securities | Mkt Outperform |
View All
Sangamo Therapeutics Inc Stock (SGMO) Latest News
Sangamo Therapeutics CFO Prathyusha Duraibabu to Step Down - MarketScreener
Sangamo Therapeutics falls on CFO retirement (SGMO:NASDAQ) - Seeking Alpha
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Sangamo Biosciences CFO Resignation Announced - TipRanks
Sangamo Therapeutics CFO Prathyusha Duraibabu resignedSEC filing - MarketScreener
What dividend growth rate does Sangamo Therapeutics Inc. offerPortfolio Performance Summary & Real-Time Stock Price Movement Reports - Lancaster City Council
Earnings Miss: Does Sangamo Therapeutics Inc. have pricing powerTrade Analysis Summary & AI Enhanced Trade Execution Alerts - Lancaster City Council
Sangamo presents epigenetic therapy for small fiber neuropathy - BioWorld MedTech
Sangamo Therapeutics Inc. Attempts Reversal From Key SupportJuly 2025 Summary & Safe Entry Momentum Stock Tips - beatles.ru
Evaluating Sangamo Therapeutics Inc. with trendline analysisJuly 2025 Drop Watch & Fast Entry High Yield Stock Tips - Newser
Is Sangamo Therapeutics Inc. undervalued by DCF analysisGlobal Markets & Weekly High Return Opportunities - خودرو بانک
Will Sangamo Therapeutics Inc. benefit from current market trends2025 Market Outlook & AI Based Buy and Sell Signals - خودرو بانک
Comparing Sangamo Therapeutics Inc. in custom built stock radarsJuly 2025 News Drivers & Weekly Breakout Opportunity Watchlist - Newser
Can Sangamo Therapeutics Inc. stock outperform in a bear marketProfit Target & Long-Term Safe Investment Plans - خودرو بانک
Sangamo reports promising data for Fabry disease gene therapy By Investing.com - Investing.com Canada
Custom strategy builders for tracking Sangamo Therapeutics Inc.July 2025 Drop Watch & Low Drawdown Trading Techniques - Newser
Is Sangamo Therapeutics Inc. benefiting from interest rate changesPortfolio Value Report & Real-Time Market Sentiment Reports - خودرو بانک
Risk adjusted return profile for Sangamo Therapeutics Inc. analyzedJuly 2025 Opening Moves & Stock Market Timing Techniques - Newser
Sangamo Therapeutics: A High-Conviction Biotech Play with a Clear Path to FDA Approval in 2026 - AInvest
Sangamo reports promising data for Fabry disease gene therapy - Investing.com
Sangamo Biosciences Reveals Promising Fabry Disease Study Results - TipRanks
Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at International Congress of Inborn Errors of Metabolism 2025 - The Manila Times
1.97 mL/min Kidney Function Improvement: Sangamo's One-Time Gene Therapy Could Transform Fabry Disease Care - Stock Titan
Will Sangamo Therapeutics Inc. stock recover after recent dropJuly 2025 Decliners & Verified Swing Trading Watchlists - Newser
Chart based analysis of Sangamo Therapeutics Inc. trendsJuly 2025 Fed Impact & Long-Term Safe Investment Ideas - Newser
Published on: 2025-09-04 02:16:59 - Newser
Will Sangamo Therapeutics Inc. outperform its industry peers2025 Price Momentum & Free Expert Verified Stock Movement Alerts - خودرو بانک
Measuring Sangamo Therapeutics Inc.’s beta against major indices2025 Price Action Summary & Step-by-Step Swing Trade Plans - Newser
What the charts say about Sangamo Therapeutics Inc. todayFed Meeting & Low Drawdown Trading Techniques - Newser
What are Sangamo Therapeutics Inc.’s recent SEC filings showingJuly 2025 Big Picture & Short-Term High Return Strategies - خودرو بانک
Smart tools for monitoring Sangamo Therapeutics Inc.’s price actionEarnings Overview Summary & Smart Money Movement Alerts - Newser
What’s the profit margin of Sangamo Therapeutics Inc.July 2025 Summary & Risk Adjusted Buy and Sell Alerts - خودرو بانک
What MACD signals say about Sangamo Therapeutics Inc.Rate Hike & Fast Momentum Stock Entry Tips - Newser
What institutional flow reveals about Sangamo Therapeutics Inc.Bull Run & Weekly High Potential Stock Alerts - Newser
Analyzing Sangamo Therapeutics Inc. with risk reward ratio charts2025 EndofYear Setup & Verified Chart Pattern Signals - Newser
Real time breakdown of Sangamo Therapeutics Inc. stock performance2025 Short Interest & Advanced Swing Trade Entry Plans - Newser
Should I buy Sangamo Therapeutics Inc. stock now2025 Biggest Moves & Daily Growth Stock Investment Tips - خودرو بانک
Sangamo Therapeutics Inc.’s volatility index tracking explainedTrade Volume Report & Short-Term Trading Opportunity Alerts - Newser
Is Sangamo Therapeutics Inc.’s ROE strong enough2025 Growth vs Value & Weekly Breakout Watchlists - خودرو بانک
Should you hold or exit Sangamo Therapeutics Inc. nowLayoff News & Risk Controlled Stock Pick Alerts - Newser
Sangamo Therapeutics Inc. stock trend outlook and recovery pathEarnings Growth Summary & Real-Time Chart Breakout Alerts - Newser
Technical analysis overview for Sangamo Therapeutics Inc. stock2025 Stock Rankings & Consistent Profit Alerts - Newser
Will Sangamo Therapeutics Inc. bounce back from current support2025 Volatility Report & Precise Swing Trade Entry Alerts - Newser
Is Sangamo Therapeutics Inc. benefiting from innovation trendsJuly 2025 Patterns & Fast Exit and Entry Trade Guides - خودرو بانک
Is Sangamo Therapeutics Inc. a cyclical or defensive stockPortfolio Profit Report & Community Verified Watchlist Alerts - خودرو بانک
CEO Moves: Should I buy Sangamo Therapeutics Inc. stock now2025 Risk Factors & Weekly Stock Breakout Alerts - خودرو بانک
Does Sangamo Therapeutics Inc. fit your quant trading modelWeekly Trade Report & Weekly Hot Stock Watchlists - Newser
What is Sangamo Therapeutics Inc.’s valuation compared to sectorJuly 2025 Opening Moves & Real-Time Chart Pattern Alerts - خودرو بانک
Analyzing Sangamo Therapeutics Inc. with multi timeframe chartsInflation Watch & Real-Time Buy Signal Alerts - Newser
Sangamo Therapeutics Inc Stock (SGMO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):